Peculiarities of IgA-nephropathy clinical course, associated with excess body mass weight


Cite item

Full Text

Abstract

Aim. Determination of peculiarities of IgA-nephropathy clinical course in overweight patients.
Methods. Retrospective study in 89 patients with IgA-nephropathy: 35 (21 male, 14 female) overweight (body mass index (BMI) 27,9±2,3 kg/m2) and 54 (30 male, 24 female) - with normal weight (BMI 21,8+2,2 kg/m2). Blood pressure, proteinuria, glomerular filtration rate (GFR), serum creatinine level, as well as ultrasound sighs of liver steatosis prevalence and serum AST, ALT and γ-GT activity were analyzed. Renal survival were calculated according to log-rank test.
Results. In overweight patients IgA-nephropathy is associated with higher blood pressure (mean BP 105,3±16,7 vs 98,7±13,7 mm Hg, p<0,05) and GFR (102±32 vs 81±27 ml/min/1,73m2, p<0,05), higher prevalence of ultrasound sighs of liver steatosis prevalence and higher serum AST, ALT and γ-GT activity levels.
Conclusion. Peculiarities of clinical course of IgA-nephropathy in overweight patients can be partly associated with deteriorated liver elimination of IgA due to nonalcoholic fatty liver disease.

References

  1. Мухин Н.А., Балкаров И.М., Максимов Н.А. Клинические проявления нарушений пуринового обмена в практике интерниста. Тер. арх. 1994; 1: 35-39
  2. Тареева И.Е. (ред.) Нефрология. Руководство для врачей. Москва. Медицина. 2000.
  3. Amore A., Roccatello D., Picciotto G, Emancipator S.N. Processing of IgA aggregates in a rat model of chronic liver disease. Clin. Immunol. Immunopathol. 1997; 84(2): 107-114
  4. Coppo R., Amore A., Roccatello D., Gianoglio B. Role of food antigens and alcohol in idiopathic nephritis with IgA deposits. Minerva Urol. Nefrol. 1991; 43(3): 171-174
  5. Lee E.Y., Chung C.H., Choi S.O. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=10576158&query_hl=4&itool=pubmed_DocSum> Immunoglobulin A nephropathy in patients with non-insulin dependent diabetes mellitus. J Korean Med Sci. 1999; 14(5):582-585
  6. Orfila C., Lepert J.C., Modesto A. et al. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=9678427&query_hl=13&itool=pubmed_docsum> IgA nephropathy complicating diabetic glomerulosclerosis. Nephron. 1998; 79(3): 279-287
  7. Chien K.L., Hsu H.C., Chao C.L. <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16707022&query_hl=22&itool=pubmed_DocSum> et al. Interaction of obesity, metabolic syndrome and Framingham risk on steatohepatitis among healthy Taiwanese: population-based nested case-control study. Cardiovasc. Diabetol. 2006; 5: 12
  8. Praga M., Hernandez E., Morales E. Clinical features and long-term outcome of obesity- associated focal segmental glomerulosclerosis. Nephrol. Dial. Transplant 2001; 15: 1790 - 1798
  9. Novak J., Julian B.A., Tomana M. et al Progress in molecular and genetic studies of IgA nephropathy. J Clin Immunol 2001; 21: 310-327
  10. Mestecky J., Tomana M., Crowley-Nowick P.A. et al. Defective galactosylation and clearance of IgA1 molecules is a possible etiopathogenic factor in IgA nephropathy. Contrib. Nephrol. 1993; 104:172-182
  11. Szцnyi L <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Sz%C3%B6nyi%20L%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>., Dobos M <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22Dobos%20M%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>., Vбsбrhelyi B <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=Search&Term=%22V%C3%A1s%C3%A1rhelyi%20B%22%5BAuthor%5D&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DiscoveryPanel.Pubmed_RVAbstractPlus>. et al. Prevalence of alpha1-antitrypsin phenotypes in patients with IgA nephropathy. Clin. Nephrol. <javascript:AL_get(this,%20'jour',%20'Clin%20Nephrol.');> 2004; 62(6): 418-422
  12. Rifai A., Fadden K., Morrison S.L. et al. The N-glycans determine the differential blood clearance and hepatic uptake of human immunoglobulins (Ig) A1 and IgA2 isotypes. J. Exp. Med. 2000; 191: 2171-2182
  13. Myllymäki J., Syrjänen J., Helin H. et al. Vascular diseases and their risk factors in IgA nephropathy. Nephrol. Dial. Transplant. 2006; 21(7): 1876-1882
  14. Jiang <http://ndt.oxfordjournals.org/cgi/content/full/23/12/3921?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&andorexacttitle=and&titleabstract=IgA+nephropathy&andorexacttitleabs=and&fulltext=IgA+nephropathy&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=1/1/2005&resourcetype=HWCIT> L., Zhang <http://ndt.oxfordjournals.org/cgi/content/full/23/12/3921?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&andorexacttitle=and&titleabstract=IgA+nephropathy&andorexacttitleabs=and&fulltext=IgA+nephropathy&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&fdate=1/1/2005&resourcetype=HWCIT> L.J., Lv L.-V. et al. Malignant hypertension in IgA nephropathy was not associated with background pathological phenotypes of glomerular lesions. Nephrol. Dial. Transplant. 2008; 23(12): 3921-3927
  15. Kurukulasuriya L.R., Stas S., Lastra G. et al. Hypertension in obesity. Endocrinol. Metab. Clin. North Am. 2008; 37(3): 647-662

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies